Manuscripts
Showing 1569 manuscripts.
Efficacy, safety, and tolerability of dispersible and immediate release abacavir/dolutegravir/lamivudine tablets in children with HIV: IMPAACT 2019 week 48 results
Citation
Helena Rabie, Dwight E. Yin, Shawn Ward, Yasha Rani, Lauren Ziemba, Kristina M. Brooks, Tim R. Cressey, Gaerolwe R. Masheto, Haseena Cassim, Jaime G. Deville, Ponego L. Ponatshego, Faeezah Patel, Linda Aurpibul, Shaun L. Barnabas, Iris Mustich, Anne Coletti, Barbara Heckman, Chelsea Krotje, Ellen Townley, Jack Moye, Sai Majji, Edward P. Acosta, Kevin Ryan, Hardik Chandasana, Cynthia H. Brothers, Ann M. Buchanan, Patricia M. Flynn, IMPAACT 2019 Study Team. Efficacy, safety, and tolerability of dispersible and immediate release abacavir/dolutegravir/lamivudine tablets in children with HIV: IMPAACT 2019 week 48 results. 2025. PMID: 40440679Year
2025
Study
IMPAACT 2019
Inflammation, antiretroviral therapy continuation, and HIV disease progression in postpartum women with HIV
Citation
Rupak SHIVAKOTI, Mark J. Giganti, Michael M Lederman, Rachel Ketchum, Sean S. Brummel, Daniela Moisi, Allen T Matubu, Sufia Dadabhai, Dhayendre Moodley, Avy Violari, Lameck Chinula, Maxensia Owor, Amita Gupta, Taha E. Taha, Patricia M. Flynn, Judith S. Currier, Mary Glenn Fowler, PROMISE Study Team. Inflammation, antiretroviral therapy continuation, and HIV disease progression in postpartum women with HIV. AIDS. 2025. PMID: 40476693Year
2025
Journal
AIDS
Study
1077BF, 1077FF
Pharmacokinetics of first-line tuberculosis drugs rifampin,
isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study
Citation
Marije Van Schalkwyk, Adrie Bekker, Eric Decloedt, Jiajia Wang, Gerhard B. Theron, Mark F. Cotton, Ahizechukwu C. Eke, Tim R. Cressey, Deo Wabwire, David E. Shapiro, Kira Bacon, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Kittipong Rungruengthanakit, Lubbe Wiesner, Edmund V. Capparelli, Alice M. Stek, Mark Mirochnick, Brookie M. Best, IMPAACT P1026s Protocol Team. Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study. Journal Antimicrobial Agents and Chemotherapy. 2025. PMID: 40741959Year
2025
Journal
Journal Antimicrobial Agents and Chemotherapy
Study
P1026S
Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV
Citation
Nicole H. Tobin, Sarah Brooker, Fan Li, Yoninah S. Cramer, Susan Rosenkranz, Robert W. Coombs, Susan E. Cohn, Carmen Zorrilla, Laura Moran, Baiba Berzins, Kimberly K. Scarsi, Catherine Godfrey, Grace M. Aldrovandi, ACTG 5316 Team. Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV. Journal of Infectious Diseases. 2025. 231: 583-594. PMID: 39479902Year
2025
Journal
Journal of Infectious Diseases
Altered milk tryptophan and tryptophan metabolites and health of children born to women with HIV
Citation
Nicole H. Tobin, Fan Li, Wentao Zhu, Kathie G. Ferbas, John W. Sleasman, Daniel Raftery, Louise Kuhn, Grace M. Aldrovandi. Altered milk tryptophan and tryptophan metabolites and health of children born to women with HIV. Research Square. 2025. 3PMID: 40166030Year
2025
Journal
Research Square
Mixing of Tecovirimat in Water to Support Oral Dosing of Infants and Children With Mpox
Citation
Z. Wei, Kristina Brooks, Sharon Nachman, Grace Aldrovandi, Timothy Wilkin, William Fischer, Jennifer Kiser, Jason Zucker. Mixing of Tecovirimat in Water to Support Oral Dosing of Infants and Children With Mpox. 2025. PMID: 39953939Year
2025
Study
A5418
Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens
Citation
Christopher Alba, Shelly Malhotra, Stephanie Horsfall, Matthew E. Barnhart, Adrie Bekker, Katerina Chapman, Coleen K. Cunningham, Patricia E. Fast, Genevieve G. Fouda, Kenneth A. Freedberg, Ameena Goga, Lusine R. Ghazaryan, Valériane Leroy, Carlyn Mann, Margaret M. McCluskey, Elizabeth J. McFarland, Vincent Muturi-Kioi, Sallie R. Permar, Roger Shapiro, Devin Sok, Lynda Stranix-Chibanda, Milton C. Weinstein, Andrea L. Ciaranello, Caitlin M. Dugdale. Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. PLoS One. 2025. 20: e0318940. PMID: 40106399Year
2025
Journal
PLoS One
Study
P1112
Influence of Distinct Maternal Cytomegalovirus-Specific Neutralizing and Fc Receptor-Binding Responses on Congenital Cytomegalovirus Transmission in HIV-Exposed Neonates
Citation
Itzayana G Miller, Aakash Mahant Mahant, Jennifer A Jenks, Eleanor C Semmes, Eric Rochat, Savannah L Herbek, Caroline Andy , Nicole S Rodgers, Justin Pollara, Linda M Gerber, Betsy C Herold, Sallie R Permar. Influence of Distinct Maternal Cytomegalovirus-Specific Neutralizing and Fc Receptor-Binding Responses on Congenital Cytomegalovirus Transmission in HIV-Exposed Neonates. Viruses. 2025. 17: 325. PMID: 40143253Year
2025
Journal
Viruses
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
Citation
Mark F Cotton, Patrick Jean-Philippe, Anne Coletti, Ellen G Chadwick, Jennifer Jao, Stephen A Spector, Mark Mirochnick, Edmund V Capparelli, Diane Costello, Joseph Szewczyk, Nicol Nicodimus, Lynda Stranix-Chibanda, Adeodata R Kekitiinwa, Violet Korutaro, Deborah Persaud, Christina Reding, Yvonne Bryson, Mary N Carrington, Bryan S Nelson, Sai Majji, Camlin Tierney, Dwight E Yin. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV. 2024. 23: 2352-3018. PMID: 38061376Year
2024
Journal
Lancet HIV
Study
P1115
Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum
Citation
Risa M. Hoffman, Sean Brummel, Lauren Ziemba, Lameck Chinula, Jeffrey S A Stringer, Frances Nakayiwa, Avy Violari, Lee Fairlie, Victoria Ndyanabangi, Teacler G. Nematadzira, Sherika Hanley, Esau João, Linda Aurpibul, Mario Dias Correa Junior, Oranich Navanukroh, Neetal Nevrekar, Gerhard Theron, Cristina Barroso Hofer, Rebecca Zash, Roger Shapiro, Nahida Chakhtoura, Ben Johnston, Chelsea Krotje, Katie McCarthy, Patrick Jean-Philippe, Paul Sax, Judith S. Currier, Shahin Lockman, VESTED Study Team. Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum. Clinical Infectious Diseases. 2024. 78: 1617-1628. PMID: 38180851Year
2024
Journal
Clinical Infectious Diseases
Study
IMPAACT 2010